Positively Aware Vosevi


sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX)

Not FDA approved for use in co-infection, but may be considered.
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6

Standard Dose

One tablet once daily with food. Each tablet contains 400 mg of sofosbuvir, 100 mg of velpatasvir, and 100 mg of voxilaprevir.

Take missed dose as soon as possible unless it is less than 12 hours until your next dose. Do not double up on your next dose.

Black Box Warning

Before starting treatment with any direct-acting antiviral (DAA), including Vosevi, patients should take a blood test to check for hepatitis B (HBV) infection. HBV infection could worsen or reactivate during or after DAA treatment, potentially leading to serious liver problems, including liver failure or death. Patients with current or past HBV infection should be monitored during HCV DAA treatment, and some may need to take HBV treatment. See HBV Reactivation on page 37 for more information and consult your medical provider.


Patients previously treated with an HCV regimen containing:

Length of treatment
1, 2, 3, 4, 5, 6 NS5A inhibitor* 12 weeks
1a or 3 Sofosbuvir** without

an NS5A inhibitor
12 weeks

* In clinical studies, this included daclatasvir, elbasvir, ledipasir, ombitasvir, and velpatasvir

** In clinical studies, this included sofosbuvir alone or in combination with any of the following: peginterferon/ribavirin, ribavirin, boceprevir, simeprevir, or telaprevir


Gilead Sciences


$29,904 / month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information